Actively Recruiting

Age: 18Years +
FEMALE
NCT06622798

Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2024-10-02

470

Participants Needed

1

Research Sites

98 weeks

Total Duration

On this page

Sponsors

S

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Lead Sponsor

A

Amoy Diagnostics

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study plans to retrospectively include 470 initial surgical specimens from 470 patients with epithelial ovarian, fallopian tube or primary peritoneal cancers who were treated with PARPi maintenance therapy in the hospital from 2018.01 to 2024.01. All patients included would be scored by the proprietary HRD ADx-GSS® algorithm with the detecting results of the three genomic statuses including heterozygous omission (LOH), telomere allelic imbalance (TAI), and large-segment translocation (LST). Finally, the correlation between the HRD scores and the prognosis of Chinese ovarian cancer patients and the efficacy of using PARPi as maintenance treatment would be explored.

CONDITIONS

Official Title

Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer diagnosed after January 2015 or platinum-sensitive recurrent patients with these cancers treated with PARPi maintenance therapy by January 2024 after chemotherapy
  • Female patients aged 18 years or older
  • Stable CA125 level, ECOG performance status 0-2, and appropriate heart, liver, and kidney function before using PARPi
Not Eligible

You will not qualify if you...

  • Other malignancies diagnosed within the past 5 years
  • Poor general health including ECOG PS score greater than 2, KPS score less than 60, cardiac insufficiency (Class III-IV), hepatic insufficiency (Child-Pugh Class C), or renal insufficiency (Stage 4-5)
  • Insufficient or poor-quality samples for testing
  • Any condition judged by the investigator to affect study conduct or result determination

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-sen memorial hospital

Guangzhou, Guangdong, China, 510060

Actively Recruiting

Loading map...

Research Team

J

Jing Li, M.D. Ph.D

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients | DecenTrialz